Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Alessandro Mantovani, Christopher D. Byrne, Enzo Bonora, et al.
Diabetes Care (2018) Vol. 41, Iss. 2, pp. 372-382
Open Access | Times Cited: 491

Showing 1-25 of 491 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1100
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis
Jie Li, Biyao Zou, Yee Hui Yeo, et al.
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 4, Iss. 5, pp. 389-398
Closed Access | Times Cited: 857
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
Qing Ye, Biyao Zou, Yee Hui Yeo, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 5, Iss. 8, pp. 739-752
Closed Access | Times Cited: 686
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 631
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 571
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, et al.
Diabetes Care (2018) Vol. 41, Iss. 8, pp. 1801-1808
Open Access | Times Cited: 495
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 437
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Reenam S. Khan, Fernando Bril, Kenneth Cusi, et al.
Hepatology (2018) Vol. 70, Iss. 2, pp. 711-724
Open Access | Times Cited: 418
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 70, Iss. 5, pp. 962-969
Open Access | Times Cited: 352
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli, Kenneth Cusi
JHEP Reports (2019) Vol. 1, Iss. 4, pp. 312-328
Open Access | Times Cited: 348
NAFLD as a driver of chronic kidney disease
Christopher D. Byrne, Giovanni Targher
Journal of Hepatology (2020) Vol. 72, Iss. 4, pp. 785-801
Open Access | Times Cited: 345
Nonalcoholic Fatty Liver Disease and the Heart
Eric Stahl, Devinder S. Dhindsa, Suegene Lee, et al.
Journal of the American College of Cardiology (2019) Vol. 73, Iss. 8, pp. 948-963
Closed Access | Times Cited: 331
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 330
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
S. Kahl, Sofiya Gancheva, Klaus Straßburger, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 298-305
Open Access | Times Cited: 266
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Sven Francque, Gyöngyi Szabó, Manal F. Abdelmalek, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 18, Iss. 1, pp. 24-39
Closed Access | Times Cited: 240
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
M Alexander, A. Katrina Loomis, Jolyon Fairburn-Beech, et al.
BMC Medicine (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 225
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong‐Ju Yoo, et al.
Clinical and Molecular Hepatology (2021) Vol. 27, Iss. 3, pp. 363-401
Open Access | Times Cited: 222
Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice
Hao Yang, Tingting Yang, Heng Cai, et al.
Phytotherapy Research (2019) Vol. 33, Iss. 12, pp. 3140-3152
Closed Access | Times Cited: 199
Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
Zhipeng Liu, Yang Zhang, Sarah E. Graham, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 2, pp. 263-276
Open Access | Times Cited: 191
The crucial role and mechanism of insulin resistance in metabolic disease
Xuefei Zhao, Xuedong An, Cunqing Yang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 188
Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications
Claudio Tana, Stefano Ballestri, Fabrizio Ricci, et al.
International Journal of Environmental Research and Public Health (2019) Vol. 16, Iss. 17, pp. 3104-3104
Open Access | Times Cited: 172
Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
Simona Marchisello, Antonino Di Pino, Roberto Scicali, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 8, pp. 1948-1948
Open Access | Times Cited: 169
Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery
Francesco Rubino, Ricardo V. Cohen, Geltrude Mingrone, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 7, pp. 640-648
Open Access | Times Cited: 167
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 160
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Zobair M. Younossi, Radhika P. Tampi, Andrei Racila, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 283-289
Open Access | Times Cited: 153
Page 1 - Next Page

Scroll to top